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Acute lung injury (ALI) and its more severe form, the acute respira- to days of a predisposing insult. In this report we will consider
tory distress syndrome (ARDS), are syndromes of acute respiratory ALI and ARDS together, although we also specifically refer
failure that result from acute pulmonary edema and inflammation. to ARDS because it has been studied as a defined entity
The development of ALI/ARDS is associated with several clinical with exclusion of patients with less severe degrees of lung in-
disorders including direct pulmonary injury from pneumonia and jury. The time course of ALI/ARDS distinguishes these syn-
aspiration as well as indirect pulmonary injury from trauma, sepsis, dromes of alveolar damage from most other lung diseases,
and other disorders such as acute pancreatitis and drug overdose. whose natural histories occur over a much longer duration,
Although mortality from ALI/ARDS has decreased in the last decade, usually years. ALI/ARDS is a major cause of acute respira-
it remains high. Despite two major advances in treatment, low VT tory failure with high morbidity and mortality in criticallyventilation for ALI/ARDS and activated protein C for severe sepsis
ill patients (1). Recent epidemiologic data indicate that the(the leading cause of ALI/ARDS), additional research is needed to
incidence of ARDS defined by consensus physiologic criteriadevelop specific treatments and improve understanding of the
may account for 36,000 deaths per year in a country the sizepathogenesis of these syndromes. The NHLBI convened a working
of the U.S. (2). There is reason to believe that this numbergroup to develop specific recommendations for future ALI/ARDS
will increase significantly in the future because of increasingresearch. Improved understanding of disease heterogeneity through
frequency of some predisposing conditions that precipitateuse of evolving biologic, genomic, and genetic approaches should
ALI/ARDS, such as sepsis (3). Although there is evidenceprovide major new insights into pathogenesis of ALI. Cellular and
that mortality in patients with ALI/ARDS may have declinedmolecular methods combined with animal and clinical studies
over the last 10 to 15 years, it remains high (30–40%), andshould lead to further progress in the detection and treatment of
this complex disease. it is an important cause of pulmonary and nonpulmonary
morbidity in patients who leave the hospital (4). Until re-
Keywords: pulmonary inflammation; critical care; genomics; pulmo- cently, there were no specific measures that altered mortality
nary edema; acute respiratory distress syndrome in ALI/ARDS, and management was exclusively expectant
and supportive, reflecting major deficiencies in our under-Acute lung injury (ALI) and the acute respiratory distress
standing of the cellular and molecular nature, pathogenesis,syndrome (ARDS) are syndromes with a spectrum of increas-
and natural history of acute alveolar injury. Recently, how-ing severity of lung injury defined by physiologic and radio-
ever, a prospective multicenter clinical trial demonstratedgraphic criteria in which widespread damage to cells and struc-
that a lung-protective ventilatory strategy could substantiallytures of the alveolar capillary membrane occurs within hours
reduce mortality (5). The results of this clinical trial suggest
that there are additional opportunities to improve outcomes
in ALI/ARDS if we can increase our fund of knowledge at
the basic, translational, and clinical levels.
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oping specific recommendations to be used by the NHLBI terial hypoxemia (PaO2/FiO2 less than 300) and bilateral pulmo-
nary opacities on the chest radiograph. Current definitions re-in planning future research in ALI/ARDS. This article sum-
marizes presentations and discussions at the Working Group quire exclusion of left atrial hypertension and overt heart failure
by clinical assessment. It is often difficult to precisely distinguishmeeting. The conference also considered trends and successes
in other fields that may be instructive and relevant to ALI/ ALI/ARDS from other diffuse inflammatory conditions of the
lung and, in some cases, from high-pressure pulmonary edema.ARDS. As an example, management of patients with acute
coronary syndromes has undergone major paradigm shifts in New diagnostic measures to address this issue would be useful.
It is not yet clear how the physiologic alterations that define therecent years because of insights generated from fundamental,
translational, and clinical investigation; this has resulted in clinical diagnosis of ALI/ARDS correlate with features that de-
fine the pathologic diagnosis, a constellation of histologic findingsdevelopment of new interventional approaches and biologic
and pharmacologic strategies that address thrombosis and termed diffuse alveolar damage (14).
Until recently, management of patients with ARDS was en-inflammation in addition to a traditional focus on lipids and
vascular remodeling and has generated ongoing investiga- tirely supportive with the objective of managing underlying in-
fections medically and surgically, providing nutritional support,tions of these critical processes (6–8). Similarly, a new treat-
ment for severe sepsis, recombinant activated protein C, has and employing mechanical ventilation for acute respiratory fail-
ure. In a large prospective NHLBI-supported study, mortality wasrecently been developed based on molecular insights relevant
to coagulation and inflammation that were then explored in reduced from 40 to 31% with the use of a ventilatory strategy
that employed low Vt (6 ml/kg) and limited plateau pressuretranslational and clinical studies (9–11). Sepsis is of particular
interest because it is a leading predisposing condition that ( 30 cm H2O) (5). The results of this trial demonstrated that
use of high Vt and high airway pressures exacerbated the pa-initiates ALI/ARDS, and it complicates ALI/ARDS induced
by other causes (1). tient’s ALI and raised interesting mechanistic questions concern-
ing interaction of lung stretch and systemic injury that mayThis report of the proceedings of the Working Group
meeting begins with a brief overview of the clinical features provide additional therapeutic approaches. Also, the results of
this trial raise interesting questions regarding how lung-protec-of ALI/ARDS followed by sections that consider (1) gaps in
our understanding of basic mechanisms underlying develop- tive ventilatory strategies work. For example, is the protection
a result of decreased mechanical injury to the lung endotheliumment of ALI, (2) how genomics and proteomics may advance
research in ALI/ARDS, (3) how genetic influences might be and epithelium, effects on the systemic compartment, or is there
also a downregulation of proinflammatory stimuli for neutrophilsstudied in patients with ALI/ARDS, (4) the challenges posed
by the heterogeneity of the clinical phenotypes in ALI/ and macrophages (15)? Also, are there beneficial effects from
the change in the carbon dioxide tension, acid-base status, andARDS, (5) how biological and clinical indices of lung injury
may be useful, and (6) how animal models can be used to effects on reactive oxygen and nitrogen species?
Despite this advance in ventilation of patients with ALI/ARDS,provide insights into lung injury. The final section summarizes
the major recommendations for future research directions. considerable work is still needed to define the basic mechanisms
that (1) initiate lung injury before institution of positive pressureThe group did not attempt to provide a comprehensive over-
view of the field, as there are many fine ones available (1, ventilation, (2) mediate progression of ongoing lung injury, (3)
cause fibrosing alveolitis and pulmonary hypertension with ex-12); instead, citations outside of the field are highlighted. The
report reflects common opinions of the participants. The chal- tensive obliteration of the lung circulation in subsets of patients,
and (4) mediate the propagation of injury from the lung to otherlenges of ALI/ARDS remain substantial, and modern and
evolving approaches in fundamental science (cell and molec- organs in many patients with ALI/ARDS.
ular biology, genomics, proteomics, disease gene discovery)
together with new approaches to clinical investigation pro- SYSTEMIC MANIFESTATIONS OF ALI/ARDS
vide substantial opportunities to improve prevention, treat-
A major feature of ALI/ARDS that distinguishes it from mostment, and outcomes in ALI/ARDS.
other lung diseases such as asthma, chronic obstructive pulmo-
nary disease, and idiopathic pulmonary fibrosis is that ALI/ARDSOVERVIEW OF ALI/ARDS
frequently has systemic components. Several of the major trig-
gering conditions for ALI/ARDS, notably sepsis, nonpulmonaryALI/ARDS is a cause of acute respiratory failure that develops
in patients of all ages from a variety of clinical disorders, includ- trauma, and shock are systemic syndromes. Furthermore, diffuse
injury and infection of the lung are major causes of systemic sep-ing sepsis (pulmonary and nonpulmonary), pneumonia (bacte-
rial, viral, and fungal), aspiration of gastric and oropharyngeal sis and the systemic inflammatory response syndrome and dys-
regulation of cellular responses in the lung may result in circulat-contents, major trauma, and several other clinical disorders in-
cluding severe acute pancreatitis, drug overdose, and blood prod- ing cytokines and other inflammatory and thrombotic mediators,
as demonstrated in clinical studies and animal models (16–18).ucts (1). Most patients require assisted ventilation with positive
pressure. The primary physiologic abnormalities are severe arte- Many patients with refractory ALI/ARDS die of multiple organ
dysfunction and/or sepsis, rather than isolated progressive respi-rial hypoxemia as well as a marked increase in minute ventilation
secondary to a sharp increase in pulmonary dead space fraction. ratory failure (1).
A consensus of the working group was that ALI/ARDS is aPatients with ALI/ARDS develop protein-rich pulmonary edema
resulting from exudation of fluid into the interstitial and airspace systemic syndrome in virtually all cases. It is important to investi-
gate the cellular and molecular mechanisms that mediate pulmo-compartments of the lung secondary to increased permeability of
the barrier. Additional pathologic changes indicate that the mech- nary injury responses to systemic insults, the factors that govern
the participation of blood cells and humoral agents that mediateanisms involved in lung edema are complex and that edema is
only one of the pathophysiologic events in ALI/ARDS. One phys- both pulmonary and systemic injury, and mechanisms that gov-
ern compartmentalized injury in the lung versus disseminationiologic consequence is a significant decrease in lung compliance
that results in an increased work of breathing (13), one of the rea- to systemic sites and distant organs. Systemic responses to stress
and injury are incompletely characterized but involve neural,sons why assisted ventilation is required to support most patients.
The clinical diagnosis of ALI is made by the presence of ar- endocrine, and pro- and anti-inflammatory mechanisms that may
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be either adaptive or pathologic (19). Animal studies indicate thelium against experimental lung injury (24), but the mecha-
nisms for this cytoprotective effect are not well understood.that neural stimulation modifies systemic responses to endotoxin
and can differentially influence cytokine accumulation in the
Lung Endotheliumlung and in systemic tissues; this phenomenon involves vagal
signaling of altered inflammatory cell function (20, 21). Molecu- The responses of lung endothelial cells are also incompletely
lar links that mediate interactions between the acute inflamma- defined even though they appear to be the first cells of the lung
tory system (innate immune effector mechanisms) and throm- to be altered in ALI/ARDS triggered by sepsis, trauma, and
botic and procoagulant responses are altered in stress and injury, other systemic conditions. The lung endothelium, in concert with
as are interactions between innate and acquired immune re- the epithelial barrier, mediates the initial change in permeability
sponses (19). and is also critical for repair and remodeling of the alveolar
Signaling pathways, such as those provided by cytokines and capillary membrane. Endothelial heterogeneity may be a factor
their receptors, may have protective or injurious effects de- in the lung’s responses to pathologic stimuli (25). Each short seg-
pending on the site of challenge and whether the inflammation ment of a rodent lung capillary possesses a few functionally dis-
is local or systemic (22). The unknown aspects of these complex tinct endothelial cells—the pacemaker cells. These cells appear
events are particularly relevant to ALI/ARDS that is induced to regulate endothelial calcium within the capillary segment by
as a part of systemic disorders such as sepsis, multiple trauma, generating intercellular calcium waves, and they may be the sites
and shock but also may be critical in order to understand the of inflammatory initiation in the capillary (26). More needs to
pathologic responses to diffuse alveolar injury caused by direct be learned about the diversity of endothelial cells, particularly re-
insults such as aspiration and microbial infection of the lung. garding how they regulate the onset of lung inflammation. Acti-
vation of endothelial cells, with functional changes that involve
both new gene expression and constitutive pathways that doCURRENT UNDERSTANDING AND SIGNIFICANT GAPS
not require new gene products, occurs in both pulmonary andIN KNOWLEDGE
systemic endothelium (27). We have an incomplete picture of the
The Working Group identified many areas in which there are molecular mechanisms that govern the responses of pulmonary
significant knowledge gaps that must be addressed in order to endothelial cells, their interaction with alveolar epithelium, and
facilitate progress in understanding ALI/ARDS and for devis- the responses of systemic endothelium in ALI/ARDS.
ing new strategies for detection, prevention, management, and
therapy. Apoptosis, Necrosis, and Fibrosis
The cells of the alveolar capillary membrane together with A comprehensive understanding of the mechanisms of apoptosis
cells of the innate immune and hemostatic systems are targets and necrosis in the initial injury and repair of lung epithelial
of damage and effectors of injury in ALI/ARDS (1). The num- and endothelial cells and other key cells involved in ALI/ARDS
bers and morphologic phenotypes of these cells are altered in is lacking. These cellular processes are likely to be central to im-
development of ALI/ARDS and its progression or resolution balances between resolution and repair versus persistence and
(14). Although much has been learned about the cell biology of progression in ALI/ARDS and can be influenced by biomechani-
the alveolar capillary membrane since the clinical syndrome of cal, inflammatory, and thrombotic stimuli (28). The mechanisms
ALI/ARDS was described, the functional responses, biochemical that govern apoptosis and necrosis in endothelial and epithelial
pathways, patterns of gene expression, molecular mechanisms of cells in the key phases of ALI/ARDS need definition. How apo-
interaction with other cells, and responses to injury remain in- ptosis and related cellular events influence fibrosing alveolitis,
completely characterized and our understanding of these pro- which is an outcome in a subset of patients with ALI/ARDS, is
cesses is embryonic at best. New approaches to ALI/ARDS are not known. Information is needed regarding signaling pathways,
likely to require comprehensive understanding of the functions patterns of gene and protein expression, and functional responses
of key interacting cells. New and evolving technologies and ana- in lung fibroblasts and mesenchymal cells that lead to dysregu-
lytic methods may provide opportunities to fill knowledge gaps. lated matrix remodeling and relentless fibrosis in some patients
with ALI/ARDS.Lung Epithelium
It is unknown how lung endothelial and epithelial injury mod-
The important role of the alveolar epithelial barrier in the patho- ify the fibrogenic response in ALI/ARDS or if apoptosis and
genesis and resolution of ALI/ARDS has been increasingly ap- necrosis affect the fibrotic process differently. Microarray analy-
preciated, including the role it plays in the production of surface- sis and assays of new protein expression using isolated cells in
active material to maintain alveolar stability as well providing parallel with the study of animal models that include fibrosis are
salt and water transport pathways for the resolution of alveolar likely to be revealing. New approaches to the cell and molecular
edema. However, our understanding of the responses of the alve- biology of fibrogenesis that are being applied to the syndrome
olar epithelium to injury remains incomplete. Disruption of alve- of idiopathic pulmonary fibrosis may be useful in clarifying the
olar epithelial integrity is a major contributor to increased per- nature of alveolar fibrosis in ALI/ARDS. A caveat is that some
meability and alveolar flooding with protein-rich edema fluid, a early events in ALI/ARDS do not involve new gene expression
hallmark of ALI/ARDS (1). Understanding of molecular signal- or changes in transcript level. Similarly, dissection of the cellular
ing pathways and mechanisms of cell–cell interaction in alveolar and molecular processes involved in endothelial death versus
epithelial cells at various stages after injury is rudimentary at repair and other key aspects of vascular wall remodeling will be
best. Although it is clear that alveolar epithelial Type II cells re- critical to understanding of the loss of pulmonary vessels and
populate the injured, denuded alveolar barrier in ALI, very little the resultant pulmonary hypertension and the increase in alveo-
is known about the intracellular signaling pathways that are ac- lar dead space that is also an outcome of a subset of patients
tivated or differential mechanisms of gene expression during with ALI/ARDS.
injury, proliferation, and differentiation. For example, we know An approach for the future treatment of ALI/ARDS could
that epithelial cells produce cytokines in response to various stim- involve stem cells to replace dying lung cells. A similar strategy
uli such as LPS or lung stretch (23), but the regulatory features has been proposed for brain, heart, and liver diseases. The in-
are not completely defined. As a second example, specific mito- flammatory response includes release of cells from the bone mar-
row such as mature and immature neutrophils and stem cells.gens such as keratinocyte growth factor can protect the lung epi-
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Elegant bone marrow reconstitution studies have demonstrated cells, which recognize pathogen-associated molecular patterns
in LPS and other microbial factors, are another group of factorsthat these stem cells have the potential to differentiate into endo-
thelial, mesenchymal, and epithelial cells (29–31). The prolifera- that are critical to inflammation and injury but were only recently
discovered. Toll-like receptors are linked by intracellular signaltive potential of fully differentiated capillary endothelial cells
and epithelial Type I cells is very poor in the lungs. The potential transduction cascades to activation of the nuclear factor-B fam-
ily of transcription factors and induction of tumor necrosis factorfor stem cells to help in the repair of injured lung tissue has not
been explored and requires a better understanding of stem cell  and other nuclear factor-B–dependent gene products. Their
engagement is central to host defense and sepsis, septic shock,release, targeting, proliferation, and differentiation in lung tis-
sue. Supplementing this release by intravenous infusion of donor and their complications including ALI/ARDS (44). The recent
explosion of information regarding toll-like receptors illustratesbone marrow–derived stem cells might be useful in ALI/ARDS,
as the pulmonary microvasculature would be the first capillary the point that much remains unknown regarding cellular re-
sponses and molecular signaling in the innate immune system.bed that these cells would encounter, enhancing their entrap-
ment and accumulation. Newly implanted endothelial cells may Precise understanding of compartmentalized versus dysregulated
systemic inflammation will depend on additional insights into thehelp restore the lung capillary network after ALI, although con-
siderable work will be needed to develop approaches for delivery biology of these cells and the molecular systems that regulate them,
including biologically active lipids, chemokines, and cytokines.of viable cells to injured areas of the lung.
Mechanical Forces and Lung Injury Thrombosis and Inflammation
Additional knowledge regarding the mechanisms that link acuteThere is incomplete understanding of how normal lungs deform
during breathing and to what stresses key lung cells are exposed inflammatory responses to thrombosis and to activation of the
coagulation cascade is also important because there is substantial(32). Lung injury may greatly alter these complex forces. Further-
more, there is uncertainty about the molecular mechanisms in- evidence that microvascular thrombosis and dysregulated intra-
volved in mechanosensing and mechanotransduction (33). Re- cellular and extracellular fibrin deposition are early events in
cent observations suggest that lung stretch induces local and/ ALI/ARDS and in experimental ALI (1, 45). Recombinant acti-
or systemic cytokine release (23), yet it remains unclear if the vated protein C, recently approved for treatment of severe sepsis,
proinflammatory deformation response is a consequence of cel- interrupts both inflammatory and thrombotic responses (10, 46,
lular stress failure (34) or of stretch-mediated signal transduc- 47). Recombinant platelet activating factor acetylhydrolase also
tion. Integrated studies examining molecular pathways, individ- may reduce mortality and organ failure in sepsis and trauma
ual cellular responses, and responses of the intact lung will be and diminish inflammatory and thrombotic signaling (47). The
required to determine how mechanical ventilation modifies the development of both of these therapies can be traced to funda-
dynamic interactions of lung cells in ALI/ARDS. mental cell and molecular biology experiments in parallel with
The effect of the mechanical stresses applied to the lung may preclinical animal studies.
extend far beyond the thoracic structures to systemic organs.
Recent studies have demonstrated that mechanical ventilation FUNCTIONAL GENOMICS, PROTEOMICS, AND OTHER
can release mediators (35) that may translocate into the systemic NEW METHODS
circulation (23). This may contribute to the high prevalence of
Modern approaches to cell and molecular biology provide significantmultiple organ failure in patients with ALI/ARDS. This hypothe-
opportunities to generate new information relevant to ALI/ARDS. Insis was strengthened by the recent low Vt study that demon-
many cases, these methods can be applied or adapted to experimentsstrated a systemic component in ALI/ARDS that was altered
with lung or other complex tissues as well as with isolated primary orby the ventilatory strategy (5). Injurious ventilatory strategies surrogate cells and can be used with appropriate modification in analysis
can lead to loss of compartmentalization in the lung and may of clinical samples. Thus, there is the potential for rapid integration of
cause translocation of mediators, endotoxin, and bacteria (36, basic and clinical data in a translational fashion. Genomic approaches
37) from the lung to the systemic circulation. Examination of using microarrays and other methods to display multiple DNA sequences
the physiological, biological, and genetic basis of stress-induced have rapidly become major tools in biologic investigation and are in-
injury to the lung in health and disease is thus a fertile area of creasingly being applied in critical care medicine. Microarray analysis
can be applied to isolated cells and normal and diseased tissues (48–50).future research.
Laser capture microdissection, real time polymerase chain reaction,
Innate Immunity and additional analytic techniques enhance the power of this technology
(51). “Functional genomic” approaches are increasingly being applied toThere is a lack of understanding of how cells of the innate
questions in pulmonary and critical care medicine (52) and have greatimmune system (neutrophils, monocytes, macrophages, natural
potential to address many unanswered questions related to changes in
killer cells, dendritic cells, and others) and cells involved in he- phenotypes of key cells in ALI/ARDS. For example, injury mechanisms
mostasis and thrombosis (platelets and endothelial cells, together mediated by release of granular enzymes or oxygen radicals by neutro-
with interacting leukocytes) are dysregulated in ALI/ARDS. phils, aggregation of neutrophils, monocytes and platelets, and activa-
Although it was originally believed that increased permeability tion of the clotting cascade use constitutive biochemical pathways and
pulmonary edema and other features of ALI/ARDS could be do not require induction of new transcripts or expression of new pro-
teins. Furthermore, transcript abundance does not unequivocally reflectexplained by endothelial and epithelial alterations alone, it is
abundance of corresponding proteins or the physiological results. Criti-now clear that acute inflammation, thrombosis, and activation
cal messenger RNAs are under stringent posttranscriptional control inof the coagulation system are involved. There is evidence that
many cases. Constitutively expressed but repressed messenger RNAsdysregulation of innate immune and thrombotic cascades con-
can be translated to proteins in response to cellular signals that are rele-tribute to both the initiation and progression of ALI/ARDS
vant to ALI/ARDS and its systemic manifestations (42, 43, 53). Thus,(1, 38). Recent studies of human leukocytes and platelets have studies of acute constitutive cellular and functional responses should
identified previously unrecognized surface receptor interactions, not be abandoned in wholesale fashion but should be used in a comple-
intracellular signaling pathways, mechanisms of gene product mentary fashion with gene analysis strategies.
expression, and functional responses that are directly relevant Evolving proteomic technologies have the potential to identify each
to ALI/ARDS and to triggering conditions such as sepsis (39–43). protein expressed in isolated cells or in complex tissues such as injured
lung and also to determine posttranslational modifications, protein–The toll-like receptors of innate immune cells and endothelial
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protein interactions, and other critical features that define phenotype or combinations of markers that can yet be used to define the
and regulate cellular function (54). Proteomic approaches can provide syndromes in general or to more precisely characterize subsets
physiologic relevance that is not inherent in measuring transcript levels or phenotypes (60). Heterogeneity is a particularly confounding
and profiles (53). New proteomic strategies based on isotope-coded problem in establishing genetic and environmental contributions
affinity tags can accurately quantify individual proteins in complex mix- to complex diseases.tures, a capability that has been lacking in the past, and can also provide
There is suggestive evidence for genetic variations in ALI/sequence information linking descriptive and quantitative proteomics
ARDS and in predisposing conditions such as sepsis. Polymor-(54). Proteomic analysis of clinical samples may be useful in establishing
phisms in genes related to inflammatory markers (tumor necrosismolecular patterns that are characteristic of individual diseases or dis-
factor , surfactant proteins, and interleukin-6), angiotensin con-ease stages (55).
The most effective use of proteomic strategies, as with genomic tech- verting enzyme, and pathogen receptors (CD14, toll-like recep-
nology, will be in combination with traditional approaches to determine tors) appear to correlate with incidence and/or outcome of sepsis
the functions of key proteins and their effects on cell and tissue behavior. (61, 62) and/or ALI/ARDS (63–65). These observations used
In many cases these experimental strategies will require new reagents, case–control association studies. Although association studies
databases, and bioinformatic tools to handle large amounts of complex pose significant logistic challenges in critically ill patient popula-
data (50, 51, 54)
tions and have limitations, they are the most immediately appli-
cable approach to ALI/ARDS. Family-based association studies
GENETICS OF ALI/ARDS and case-controlled association studies may be beneficial to ex-
plore in well-defined subgroups of patients with ALI/ARDS.A major gap in our knowledge is the extent to which genetic
Positional cloning has been used with success in the study offeatures interact with environmental variables to influence sus-
complex diseases. However, availability of the sequence of theceptibility to ALI/ARDS. In sepsis, trauma, and other triggering
human genome and new technologies that link gene discoveryconditions, only a subset of patients develops ALI/ARDS even
to biologic function will likely provide accelerated insight intoamong those in whom the pathologic stimuli are apparently
multifactorial syndromes such as ALI/ARDS and will use newequivalent (1, 3, 5, 11), suggesting that there are genetic features
that may influence its onset. Similarly, we do not know what ge- approaches (66). These include identification and establishment
netic features influence the natural history of ALI/ARDS once of the significance of single-nucleotide polymorphisms and other
it is established or how genetic variables interact with environ- variations in the human genome; methods to further characterize
mental factors to determine resolution and repair versus persis- quantitative trait loci; identification of new pathways of cell func-
tence and progression of acute lung inflammation and injury. tion and regulation and refined analysis of known metabolic path-
Furthermore, we have little understanding of genetic features ways based on coregulated genes; new analysis of mechanisms
that regulate compartmentalization of inflammation and injury of transcriptional and posttranscriptional regulation, protein–
in one case and engender a systemic response in another (19). protein interactions, and cross talk between signaling cascades;
Human genetic syndromes are commonly classified as simple genotype–phenotype correlations that identify gene–gene inter-
Mendelian disorders or as multifactorial complex diseases. In actions and other modifying features that lead to variations in the
Mendelian diseases, a mutation in one or both alleles of a single clinical phenotypes; and new approaches to dissecting interactions
disease gene leads to a pathologic phenotype, whereas complex between genes and environment involving epidemiologic studies
genetic syndromes are generally caused by mutations in more of carefully characterized populations. Robust databases that
than one gene with significant contributions from the environ- link disease records, family records, and other data sets that can be
ment usually influencing the manifestations of the disease. Addi- integrated for biomedical research will be important tools. Appli-
tional features of complex genetic diseases include large pheno- cation of the new genetic approaches will also require parallel re-
typic variation, incomplete penetrance, late age of onset, the finement of the clinical phenotypes of diseased patients and con-
potential for locus heterogeneity, and lack of easily identified trol populations, a particular challenge in the case of ALI/ARDS.
large families because of a complicated pattern of heritability. Postgenomic approaches will continue to depend on geneti-
The frequency of alterations in disease genes is variable in multi- cally modified mice and other model systems. Mapping of traits,
factorial disorders, potentially making them difficult to identify. generation of knockouts and transgenics, and mutational strate-
Recent identification of alleles of the NOD 2 gene as variants gies with genome-wide analysis are highly tractable in mouse
that predispose to Crohn’s disease (56, 57) illustrates many of models and can circumvent some of the problems of human
these points. Complex human disorders may also result from patient populations, including heterogeneity. Genetic and geno-
multiple rare variant mutations in a single gene leading to similar mic approaches using mice and other model species have promise
or identical phenotypes (58). Finally, many traits of clinical sig- for dissection of the complexity of cardiovascular diseases (67)
nificance in complex diseases have continuous variation rather and other disorders. Some of these approaches have recently
than discrete phenotypes; interacting genes that influence varia- been applied in mouse models of lung injury (68).
tion in these traits are located in chromosomal regions termed
quantitative trait loci. Mapping quantitative trait loci to identify HETEROGENEITY OF PHENOTYPE IN ALI/ARDS
genes involved in polygenic traits has been used for analysis of
The heterogeneity of inciting factors and outcomes in ALI/ARDScomplex human diseases, including asthma, arteriosclerosis, and
creates complexity and uncertainty in the study of this syndrome.diabetes (59).
In order to better understand specific mechanisms of ALI underIn most cases, susceptibility to ALI/ARDS, and the natural
different clinical conditions as well as to probe genetic and envi-history of these syndromes once they are established, is likely
ronmental influences, it is important that more information begoverned by genetic features together with environmental vari-
obtained regarding characterization of subgroups of patients withables in the complex fashion outlined previously. Studies of large
ALI/ARDS. For example, the incidence, natural history, andfamilies, evaluation of large archives of small families, and analy-
outcome of ALI/ARDS induced by sepsis and trauma are quitesis of affected sibling pairs are major gene discovery approaches
different in some senses, but the factors contributing to thisthat have been used in asthma and other complex diseases; how-
heterogeneity are not clear (1).ever, these investigational tools are not available for ALI/ARDS.
Patients develop pneumonia from several different etiologies,Furthermore, there is substantial heterogeneity in ALI/ARDS (see
next section), and there are no unique, easily measured markers including gram-positive or gram-negative bacteria, viruses, or even
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fungi or parasites, particularly in the presence of immunosup- mains associated with cellular plasma membranes and is not
released into solution (27). Thus, it may not be detected inpression, and the signaling pathways that regulate the inflamma-
tory response to any particular organism depend on the initial bronchoalveolar lavage or other fluid samples and/or its concen-
tration in fluid samples may bear little relationship to its signalingmolecular interactions between the host cells and the organism
(39, 44). A better understanding of bacterial genetics and the actions. Also, antigenic measurement of cytokines in edema fluid
or bronchoalveolar lavage may not correlate well with biologicalspecific virulence factors of infecting bacteria should provide new
approaches to understanding susceptibility to pneumonia and activity. Both interleukin- and tumor necrosis factor  can be
detected by immunoassays in the distal airspaces of the lung inALI/ARDS both as a cause of injury and as a cause of nosocomial
pneumonia in patients with ALI/ARDS (17). A better under- patients with early ALI, but interleukin-1 has more biological
activity than tumor necrosis factor  (70).standing of why some patients with sepsis develop ALI is needed.
Is there a host susceptibility to sepsis so that patients who are
more likely to upregulate gene expression for proinflammatory ANIMAL MODELS OF LUNG INJURY
cytokines are therefore more likely to develop ALI? This hy-
Animal studies that have attempted to mimic human ALI/ARDSpothesis is plausible but other factors may also be involved, such
have been useful and will likely continue to provide valuable ob-as the ability of the host to confine an infection to a localized
servations regarding both the mechanisms underlying the patho-area. For example, the ability to mount a local proinflammatory
genesis, progression, and resolution of this syndrome and waysresponse may be important in containing bacterial infection to
in which its course can be modulated therapeutically (39, 68,one portion of the lung, thus preventing dissemination of cyto-
71–76). The lack of an animal model that unequivocally mimicskines and bacterial products to the circulation that could result
key aspects of human ALI/ARDS has been limiting in mechanis-in multiple organ failure and diffuse lung injury if not locally
tic studies and in providing meaningful and rapid extrapolationscontained (19). A more detailed understanding of the pathogene-
to the clinical syndrome. Furthermore, there is uncertainty assis of clinical lung injury, including biochemical markers, studies
to which of the many available animal models best reflects theof lung pathology, and integrated studies using genomics and
human clinical syndrome. Animal models are usually monitoredproteomics may provide more insight into individual patient
over a shorter term than the human syndrome, which requiressusceptibility and potentially identify ALI/ARDS subgroups. It
hours or days to develop. Most animal models do not includeis possible that one or more specific markers may apply to one
ventilation and fluid management interventions, features thatphenotypic ALI/ARDS subgroup but not to another. Similar
may be crucial factors in determining outcome in humans. Aapproaches are being used in other human diseases (55).
major question is whether the pathogenesis of human ALI/ARDS
varies with risk factors, such as trauma and sepsis. This has ledCLINICAL AND BIOCHEMICAL PREDICTORS OF ALI
to studies comparing and contrasting the mechanisms of injury in
animal models of endotoxin and hemorrhagic shock–associatedThe search for biochemical and clinical predictors or markers
of ALI has been hampered by a number of factors, including ALI (71). Administration of LPS alone does not completely mimic
the systemic or pulmonary effects of bacteremia or endotoxemia,(1) the lack of correlation between the clinical diagnosis and
the pathogenesis, (2) the recognition that patients at risk for and contributing to the use of more complex models such as cecal
ligation and puncture (72). Furthermore, many workshop par-with ALI are heterogeneous, (3) the continuous discovery of
new mediators and modulators of inflammation, (4) the recogni- ticipants suggested that two-hit models (73–76) might be more
appropriate to reflect common comorbidities and risk factorstion that the development of ALI is likely the result of a balance
of mediators and modulators of inflammation, and (5) the increas- commonly present in these patients. Continued study of the
heterogeneity of precipitating causes of ALI/ARDS is needed.ing awareness of the importance of correlating biochemical mark-
ers with physiologic variables. Although the recognition of these The traditional knockout and transgenic approaches to delete
or add a gene will remain useful, but more sophisticated approachesfactors has complicated the quest for markers in ALI/ARDS, each
of these factors provides unique new opportunities for their study. to modify genes and to conditionally express or knock out genes
are needed to better understand the role of particular moleculesPatients with a higher severity of illness score are more likely
to develop ALI/ARDS and die of lung injury. However, the and pathways (67). In combination, these studies will elucidate
interactions and redundancies in pathways and molecular func-search for a pulmonary-specific variable has been challenging.
Indices of hypoxemia have not been predictive of clinical out- tions. Furthermore, cell- and organ-specific approaches, either
through bone marrow reconstitution or selection and manipula-come (5). One recent study established that an elevated dead
space fraction has an independent predictive power for identi- tion of promoter function, will also prove valuable for under-
standing the complexities of cell function and interaction in thefying patients more likely to die (13). This finding needs to be ex-
plored in conjunction with detailed biochemical studies and lungs and to provide potential therapeutic targets. Furthermore,
animal studies can also facilitate understanding of the heteroge-other methods to determine the pathologic and physiologic basis
for a high dead space fraction. Procoagulant mechanisms are neity of phenotype using chemical mutagenesis or gene mapping
and linkage studies in mice of specific genetic backgrounds thatactivated both in the circulation and the distal airspaces of the
lung in patients with early ALI and may ultimately provide display variable responses to experimental lung injury. Finally,
the availability of the rat genome will be extremely useful (77),markers of alveolar capillary damage or vascular occlusion (45).
More work is needed to evaluate products of endothelial injury as opportunities for comprehensive physiologic studies of lung
injury are better in rats than in mice.as well as mechanisms that reflect endothelial, neutrophil, and
thrombotic interactions. Markers of endothelial injury such as Animal models that facilitate “fast track” analysis of thera-
peutic leads and combinations of therapeutic agents would bevon Willebrand factor that reflect pulmonary and systemic endo-
thelial injury may prove useful. expected to accelerate clinical application of basic discoveries.
One approach that may prove useful for identifying clinical tar-Although measurement of soluble biochemical markers in
plasma, edema fluid, and bronchoalveolar lavage fluid has pro- gets would involve gene profiling and proteomic evaluation of
tissue from one or more animal models of lung injury that reflectvided insights into mechanisms of lung injury (69), they may not
necessarily reflect critical molecular events at the cell surface. phenotypic subgroups of ALI/ARDS. The effect of agents having
the potential to diminish the severity of systemic and pulmonaryIn juxtacrine signaling between cells, the signaling molecule re-
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injury on genomic and proteomic variables could then provide 5. Future research should build in part on the recently dem-
mechanistic insights to determine if similar pathways were being onstrated new treatments for ALI/ARDS and sepsis.
altered in human ALI/ARDS and help to narrow the field of More basic research is needed to detail the cellular, mo-
candidate genes for human ALI/ARDS. Animal models could lecular, and physiologic mechanisms that protect the lung
and should focus on both systemic and pulmonary injury and from biomechanical stress and injury and potentially
may also provide insights about the interactions between them. modulate systemic inflammation. More studies are needed
For example, recent studies of an intraperitoneal sepsis model in to explore the role of the inflammatory and coagulation
rats using a limited gene microarray revealed interesting results pathways in inducing organ injury in sepsis and other
regarding the host response in lung, kidney, brain, and lymphoid injury states and in modulating ALI. Both basic and clini-
tissues (72). Studies in animal models with clinical relevance to cal studies are needed. Although ARDS is a uniquely
ALI/ARDS would facilitate the design of clinical trials focused human disease, animal models are relevant to several
on diminishing clinical lung injury and the associated nonpulmo- different features of clinical ALI. Better understanding
nary organ dysfunction, including renal failure and hepatic and is needed to determine which animal models are most
hematologic dysfunction, as well as the consequences of shock relevant to the human disease. “Two hit” models may
states produced by sepsis and trauma. better reflect comorbid conditions and other pre-existing
variables and may be more informative in dissecting the
CONCLUSIONS AND RECOMMENDATIONS roles of the innate immune system and specific mecha-
nisms of lung injury. Animal models that focus on sys-There are major unanswered questions about ALI/ARDS that
temic as well as pulmonary injury may prove to be particu-will require continued research efforts at the basic, translational,
larly relevant to human ALI. Genetically altered mouseand clinical levels. Recent successes in the treatment of critically
models will also be useful. Lung- and tissue-specific condi-ill patients provide an excellent opportunity for rapid progress, as
tional knockouts, overexpression of candidate genes, anddo new and evolving biologic, genomic and genetic approaches.
Investigations and collaborative efforts that include cellular and other genetic models should be of value in dissecting
mechanistic studies combined with animal and clinical studies the host response to pathological conditions that model
will be the key to improving detection and treatment of this human lung injury.
complex syndrome. 6. Because infection is the most frequent cause of ALI/
ARDS, the influence of bacterial and viral genetics on1. Continued support for high quality collaborative multi-
host response that influence lung injury needs to be bettercenter clinical trials, as well as individual investigator-
understood.initiated studies, is crucial for continued progress in pre-
7. Research to study and improve the resolution of ALI,vention and treatment of ALI/ARDS. Studies of multiple
including mechanisms to modulate clearance of edemadrug treatments for this complex syndrome may be needed.
fluid, soluble and insoluble proteins, inflammatory cells,Future studies could be broadened to include common
comorbid conditions such as renal failure and sepsis. Sup- and remodeling of the lung is needed. The potential for
port for mechanistic/pathogenic investigations in con- enhancement of lung repair with stem cell therapy should
junction with clinical trials is essential. The smaller clinical be explored.
investigations conducted at single centers continue to 8. More emphasis is needed on understanding cell-to-cell
have value because of complex patient populations and communication in the lung, including the mechanisms that
to test new treatments for evidence to support further transmit signals between endothelial and epithelial cells
evaluation in larger multicenter trials. and mechanisms of cell-to-cell interaction in inflamma-
2. Strategies for robust and facile analysis of genomic and tory and thrombotic responses. The signals and mecha-
proteomic data from studies in animal models, including nisms that determine normal cell turnover and influence
genome sequencing databases, tissue- and species-specific apoptosis and necrosis in lung injury need to be eluci-
microarrays, online archiving of serial microarray and dated. Advanced imaging modalities, such as microcom-
other data, and other resources should facilitate transla- puterized tomography and confocal microscopy, should
tion of animal experiments to clinical relevance. be refined to generate data on cell and parenchymal mi-
3. Studies that correlate biochemical and biological markers crostrains in intact lungs, so that molecular research on
with clinical variables should continue in order to address
mechanosensing and mechanotransduction can be inter-the issue of heterogeneity, to more precisely define the
preted in an appropriate context. Similarly, refined im-phenotypes of patients with ALI/ARDS, to permit ge-
aging techniques that are applicable to inflammatory cellnetic analysis, and to facilitate clinical trials of new candi-
trafficking and cell–cell interactions will likely be infor-date therapies. Panels of biological and biochemical mark-
mative.ers, in conjunction with clinical indices, may be needed
9. Studies that use cell biological approaches including sin-to generate a prognostic index in ALI/ARDS. Markers
gle and multiple cell type cultures should be integratedthat reflect systemic events (coagulation and inflamma-
with animal and human studies.tory markers) as well as those that reflect alterations in
10. More knowledge is needed to study the extent to whichlung endothelial and epithelial cells and fibrotic processes
genetic factors influence the development, severity andshould be included. Pulmonary edema fluid, circulating
time course of development and resolution of ALI/ARDScells, DNA samples, and plasma should be obtained in
as well as the development of multiple organ failure andclinical studies.
other systemic sequelae. Development of genetic tools and4. Accrual and collections of well-characterized lung tissue
resources specifically relevant to ALI/ARDS, triggeringsamples from patients with ALI/ARDS will facilitate ap-
conditions, and systemic manifestations will likely facili-plication of modern analytic techniques (laser capture
tate characterization of genetic and environmental vari-microdissection, microarray interrogation, proteomic anal-
ables that influence ALI. Case–control association stud-ysis) to define the molecular phenotype of key lung cells
and structures. ies, although of lesser power, may be useful.
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